NASDAQ : CLDX
Celldex Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 30.1 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.36B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Celldex Therapeutics, Inc. (CLDX) reported revenue of 158.00K USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 158.00K | 1.54M | 7.02M | 6.88M | 2.36M | 4.65M |
| Cost of Revenue | 278.81M | 245.07M | 163.55M | 118.01M | 82.26M | 53.31M |
| Gross Profit | -278.65M | -243.53M | -156.53M | -111.13M | -79.90M | -48.66M |
| Selling, General & Admin | 47.18M | 43.84M | 38.55M | 30.91M | 27.20M | 20.49M |
| Operating Expenses | 47.18M | 43.84M | 38.55M | 30.91M | 27.20M | 20.49M |
| Operating Income | -325.83M | -287.37M | -195.08M | -142.04M | -107.10M | -69.15M |
| Interest & Investment Income | 25.28M | 28.61M | 37.22M | 13.11M | 2.91M | 505.00K |
| EBT Excluding Unusual Items | -300.55M | -258.76M | -157.86M | -128.93M | -104.19M | -68.64M |
| Legal Settlements | -12.50M | -15.00M | ||||
| Other Unusual Items | 6.86M | 1.41M | ||||
| Pretax Income | -300.55M | -258.76M | -157.86M | -141.43M | -112.33M | -70.74M |
| Income Tax Expense | -227.00K | |||||
| Net Income | -300.55M | -258.76M | -157.86M | -141.43M | -112.33M | -70.51M |
| Net Income to Common | -300.55M | -258.76M | -157.86M | -141.43M | -112.33M | -70.51M |
| Shares Outstanding (Basic) | 69.34M | 66.42M | 64.39M | 48.45M | 46.89M | 42.87M |
| Shares Outstanding (Diluted) | 69.34M | 66.42M | 64.39M | 48.45M | 46.89M | 42.87M |
| EPS (Basic) | -4.33 | -3.90 | -2.45 | -2.92 | -2.40 | -1.64 |
| EPS (Diluted) | -4.33 | -3.90 | -2.45 | -2.92 | -2.40 | -1.64 |
| Free Cash Flow | -242.10M | -213.66M | -159.70M | -109.11M | -105.56M | -62.16M |
| Free Cash Flow Per Share | -3.49 | -3.22 | -2.48 | -2.25 | -2.25 | -1.45 |
| Operating Margin | -206,220.25% | -18,599.81% | -2,778.89% | -2,063.66% | -4,543.74% | -1,486.73% |
| Profit Margin | -190,220.89% | -16,748.03% | -2,248.76% | -2,054.76% | -4,765.59% | -1,516.04% |
| Free Cash Flow Margin | -153,231.01% | -13,829.06% | -2,274.89% | -1,585.19% | -4,478.57% | -1,336.44% |
| EBITDA | -322.43M | -283.99M | -191.90M | -139.03M | -104.20M | -66.08M |
| D&A For EBITDA | 3.40M | 3.38M | 3.18M | 3.01M | 2.90M | 3.07M |
| EBIT | -325.83M | -287.37M | -195.08M | -142.04M | -107.10M | -69.15M |
| Revenue as Reported | 158.00K | 1.54M | 7.02M | 6.88M | 2.36M | 4.65M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 47.45M | 28.87M | 28.36M | 34.81M | 29.43M | 39.14M |
| Short-Term Investments | 670.13M | 489.70M | 696.92M | 388.78M | 275.52M | 369.11M |
| Cash & Short-Term Investments | 717.59M | 518.57M | 725.28M | 423.60M | 304.95M | 408.25M |
| Receivables | 230.00K | 2.02M | 700.00K | 2.63M | 347.00K | 172.00K |
| Prepaid Expenses | 7.11M | 14.08M | 21.18M | 5.47M | 12.39M | 2.42M |
| Total Current Assets | 724.93M | 534.66M | 747.16M | 431.69M | 317.69M | 410.84M |
| Property, Plant & Equipment | 14.79M | 7.77M | 8.24M | 6.64M | 7.75M | 6.52M |
| Other Intangible Assets | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M |
| Other Long-Term Assets | 15.43M | 13.36M | 9.75M | 107.00K | 104.00K | 104.00K |
| Total Assets | 782.35M | 582.98M | 792.34M | 465.63M | 352.74M | 444.65M |
| Accounts Payable | 14.68M | 1.18M | 3.27M | 3.49M | 3.34M | 1.23M |
| Accrued Expenses | 43.86M | 47.03M | 33.84M | 22.03M | 12.84M | 12.00M |
| Current Portion of Leases | 1.56M | 1.55M | 1.45M | 1.61M | 1.45M | 1.75M |
| Current Unearned Revenue | 1.23M | 12.00K | 3.06M | 60.00K | 433.00K | |
| Other Current Liabilities | 1.23M | 930.00K | 930.00K | 930.00K | 1.12M | |
| Total Current Liabilities | 61.33M | 50.99M | 39.50M | 31.12M | 18.61M | 16.53M |
| Long-Term Leases | 3.35M | 784.00K | 2.36M | 928.00K | 2.59M | 1.30M |
| Long-Term Unearned Revenue | 2.43M | |||||
| Long-Term Deferred Tax Liabilities | 1.61M | |||||
| Other Long-Term Liabilities | 3.11M | 3.47M | 4.40M | 5.33M | 7.35M | |
| Total Liabilities | 67.78M | 55.82M | 45.34M | 36.46M | 26.53M | 25.18M |
| Common Stock | 79.00K | 67.00K | 66.00K | 56.00K | 47.00K | 47.00K |
| Additional Paid-In Capital | 2.68B | 2.34B | 2.30B | 1.82B | 1.58B | 1.56B |
| Retained Earnings | -1.97B | -1.81B | -1.56B | -1.40B | -1.26B | -1.14B |
| Comprehensive Income & Other | 1.30M | 3.63M | 3.31M | 3.31M | 1.26M | 1.89M |
| Shareholders' Equity | 714.56M | 527.16M | 747.00M | 429.17M | 326.20M | 419.48M |
| Total Liabilities & Equity | 782.35M | 582.98M | 792.34M | 465.63M | 352.74M | 444.65M |
| Total Debt | 4.90M | 2.34M | 3.81M | 2.54M | 4.03M | 3.04M |
| Net Cash (Debt) | 712.68M | 516.24M | 721.47M | 421.06M | 300.92M | 405.21M |
| Net Cash Per Share | 10.28 | 7.77 | 11.20 | 8.69 | 6.42 | 9.45 |
| Filing Date Shares Outstanding | 78.53M | 66.57M | 66.38M | 55.90M | 47.21M | 46.74M |
| Total Common Shares Outstanding | 78.50M | 66.55M | 66.37M | 55.88M | 47.20M | 46.73M |
| Working Capital | 663.61M | 483.67M | 707.66M | 400.57M | 299.08M | 394.31M |
| Book Value Per Share | 9.10 | 7.92 | 11.25 | 7.68 | 6.91 | 8.98 |
| Tangible Book Value | 687.37M | 499.98M | 719.82M | 401.98M | 299.01M | 392.29M |
| Tangible Book Value Per Share | 8.76 | 7.51 | 10.84 | 7.19 | 6.33 | 8.39 |
| Machinery | 17.18M | 17.39M | 16.00M | 15.26M | 14.51M | |
| Construction In Progress | 1.72M | 139.00K | 787.00K | 498.00K | 632.00K | |
| Leasehold Improvements | 10.34M | 10.29M | 9.65M | 9.61M | 9.53M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -300.55M | -258.76M | -157.86M | -141.43M | -112.33M | -70.51M |
| Depreciation & Amortization | 3.40M | 3.38M | 3.18M | 3.01M | 2.90M | 3.07M |
| Loss (Gain) From Sale of Assets | 10.00K | 12.00K | 16.00K | 2.00K | -24.00K | |
| Asset Writedown & Restructuring Costs | 3.50M | |||||
| Loss (Gain) From Sale of Investments | -4.23M | -5.86M | -15.75M | -6.22M | 844.00K | -3.21M |
| Stock-Based Compensation | 34.64M | 36.22M | 34.24M | 23.89M | 15.61M | 8.95M |
| Other Operating Activities | -6.86M | -1.63M | ||||
| Change in Accounts Receivable | -140.00K | -1.31M | 1.93M | -2.28M | -175.00K | 1.57M |
| Change in Accounts Payable | 27.51M | 11.03M | 11.63M | 9.38M | 3.12M | 3.65M |
| Change in Other Net Operating Assets | 3.79M | 4.34M | -35.16M | 6.36M | -6.85M | -6.28M |
| Operating Cash Flow | -235.57M | -210.94M | -157.78M | -107.29M | -103.73M | -60.91M |
| Capital Expenditures | -6.54M | -2.71M | -1.92M | -1.82M | -1.83M | -1.25M |
| Sale of Property, Plant & Equipment | 69.00K | 27.00K | ||||
| Investment in Securities | -60.59M | 211.79M | -288.21M | -103.96M | 91.70M | -214.93M |
| Investing Cash Flow | -67.13M | 209.07M | -290.13M | -105.78M | 89.94M | -216.16M |
| Issuance of Common Stock | 327.11M | 2.39M | 441.45M | 218.46M | 4.08M | 272.37M |
| Financing Cash Flow | 327.11M | 2.39M | 441.45M | 218.46M | 4.08M | 272.37M |
| Net Cash Flow | 24.41M | 515.00K | -6.46M | 5.38M | -9.71M | -4.69M |
| Free Cash Flow | -242.10M | -213.66M | -159.70M | -109.11M | -105.56M | -62.16M |
| Free Cash Flow Margin | -153,231.01% | -13,829.06% | -2,274.89% | -1,585.19% | -4,478.57% | -1,336.44% |
| Free Cash Flow Per Share | -3.49 | -3.22 | -2.48 | -2.25 | -2.25 | -1.45 |
| Levered Free Cash Flow | -133.08M | -125.54M | -91.67M | -46.70M | -58.02M | -29.71M |
| Unlevered Free Cash Flow | -133.08M | -125.54M | -91.67M | -46.70M | -58.02M | -29.71M |
| Change in Working Capital | 31.16M | 14.06M | -21.60M | 13.46M | -3.90M | -1.05M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 2.28B | 1.80B | 1.68B | 2.17B | 2.10B | 1.80B |
| Enterprise Value | 1.57B | 1.22B | 923.61M | 1.94B | 1.78B | 1.38B |
| Last Close Price | 29.04 | 27.16 | 25.27 | 39.66 | 44.57 | 38.64 |
| PS Ratio | 14,433.53 | 1,168.13 | 238.82 | 315.12 | 890.64 | 387.68 |
| PB Ratio | 3.19 | 3.42 | 2.24 | 5.05 | 6.43 | 4.30 |
| P/TBV Ratio | 3.32 | 3.61 | 2.33 | 5.40 | 7.02 | 4.60 |
| EV/Sales Ratio | 9,922.88 | 792.34 | 131.57 | 281.34 | 754.94 | 297.37 |
| Debt / Equity Ratio | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
| Net Debt / Equity Ratio | -1.00 | -0.98 | -0.97 | -0.98 | -0.92 | -0.97 |
| Net Debt / EBITDA Ratio | 2.21 | 1.82 | 3.76 | 3.03 | 2.89 | 6.13 |
| Net Debt / FCF Ratio | 2.94 | 2.42 | 4.52 | 3.86 | 2.85 | 6.52 |
| Asset Turnover | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | 0.01 |
| Quick Ratio | 11.71 | 10.21 | 18.38 | 13.69 | 16.41 | 24.71 |
| Current Ratio | 11.82 | 10.48 | 18.91 | 13.87 | 17.07 | 24.86 |
| Return on Equity (ROE) | -43.88% | -40.62% | -26.84% | -37.45% | -30.13% | -22.43% |
| Return on Assets (ROA) | -27.62% | -26.12% | -19.38% | -21.70% | -16.79% | -12.70% |
| Return on Capital Employed (ROCE) | -45.20% | -54.00% | -25.90% | -32.70% | -32.10% | -16.20% |
| Earnings Yield | -14.92% | -14.34% | -9.42% | -6.52% | -5.35% | -3.91% |
| FCF Yield | -10.62% | -11.84% | -9.53% | -5.03% | -5.03% | -3.45% |
| Buyback Yield / Dilution | -4.49% | -3.15% | -32.91% | -3.33% | -9.37% | -44.64% |